Company partner
On September 20 12, the company signed a strategic cooperation agreement with the world's top 500 health care and beauty group led by pharmacies. The strategic cooperation project was approved by the Ministry of Commerce and the China Securities Regulatory Commission on 20 14, and the stock issue was completed. The company has now become the first Chinese-foreign cooperative listed company in China pharmaceutical circulation industry.
The company's main business
Based on pharmaceutical circulation, the company focuses on pharmaceutical supply chain service business and healthy retail chain business. Now, the company has developed from a regional single enterprise to a trans-regional, collectivized and networked super-large enterprise with nearly 70 molecular companies. The market covers Jiangsu, Anhui, Fujian and parts of Yunnan, Hubei and Sichuan. It is the designated unit of medical equipment reserve in Jiangsu, Anhui and Fujian, the designated unit of medical equipment reserve in the General Logistics Department of the People's Liberation Army, and the unit of vice president china association of pharmaceutical commerce.
Business scope of the company
Permitted items: Category III medical device leasing; Drug wholesale; Drug retail; Drug import and export; The third kind of medical device management; Food sales; Road freight transport (excluding dangerous goods); Cosmetic production; Category II value-added telecommunications services (projects subject to approval according to law can only be operated after approval by relevant departments, and the specific business projects are subject to the approval results) General projects: professional design services; Property management; Non-residential real estate leasing; Minibus rental business services; Loading and unloading; Artificial intelligence hardware sales; Intelligent robot sales; Intelligent material handling equipment sales; Information technology consulting services; Technical service, technical development, technical consultation, technical exchange, technology transfer and technology popularization; Sales of special chemical products (excluding dangerous chemicals); Sales of chemical products (excluding licensed chemical products); Wholesale of sporting goods and equipment; Retail of sporting goods and equipment; Sales of special teaching instruments; Sales of experimental analytical instruments; The second kind of medical equipment leasing; Sales of first-class medical devices; Sales of second-class medical devices; Import and export of goods; Information consulting services (excluding licensed information consulting services), etc.
Honors won by the company
In April, 2022, the Special Medicine Group of the First Pharmacy of Nanjing Pharmaceutical Co., Ltd. was awarded the "Nanjing Worker Pioneer".
In July, 2022, it ranked 28th1on the Fortune China 500 list in 2022.
In July 2023, he was selected as one of the top 500 listed companies in China in 2023, ranking 257th.
On July 25th, 2023, he was selected as the 300th in the 2023 Fortune China 500 list.